Complementing Insulin Therapy to Achieve Glycemic Control

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Advances in Therapy

• Publication date

  2013-06-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12325-013-0039-yPMID 23797471
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 2012;35:723–730

  2013cited by this paper
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials

  2013cited by this paper
• Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea

  2013cited by this paper
• Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.

  2013cited by this paper
• Types and origins of diagnostic errors in primary care settings.

  2013cited by this paper
• Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

  2013cited by this paper
• Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379

  2013cited by this paper
• Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

  2013cited by this paper
• Efficacy and Safety of Linagliptin as Add-on Therapy to Basal Insulin in Patients With Type 2 Diabetes

  2012cited by this paper
• Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets

  2012cited by this paper
• Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.

  2012cited by this paper
• Effect of initial combination therapy with sitagliptin and metformin on β‐cell function in patients with type 2 diabetes

  2012cited by this paper
• Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin

  2012cited by this paper
• The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

  2012cited by this paper
• Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

  2012influential reference
• Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

  2012cited by this paper
• Glucose control in diabetes: the impact of racial differences on monitoring and outcomes

  2012cited by this paper
• Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

  2012cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012influential reference
• Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

  2012cited by this paper
• Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

  2012cited by this paper
• Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin

  2012cited by this paper
• Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

  2012cited by this paper
• Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men

  2011cited by this paper
• Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations

  2011influential reference
• Effect of linagliptin monotherapy on glycaemic control and markers of β‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

  2011cited by this paper
• Relative Expression of a Dominant Mutated ABCC8 Allele Determines the Clinical Manifestation of Congenital Hyperinsulinism

  2011cited by this paper
• Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24‐week randomized study 1

  2011cited by this paper
• Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

  2011cited by this paper
• Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

  2011cited by this paper
• Prevalence and Characteristics of Painful Diabetic Neuropathy in a Large Community-Based Diabetic Population in the U.K.

  2011cited by this paper
• Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label long‐term extension study

  2011cited by this paper
• Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes

  2011cited by this paper
• Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial

  2011cited by this paper
• The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.

  2011cited by this paper
• Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study

  2011cited by this paper
• Evidence Linking Hypoglycemic Events to an Increased Risk of Acute Cardiovascular Events in Patients With Type 2 Diabetes

  2011cited by this paper
• SGLT2 inhibition — a novel strategy for diabetes treatment

  2010cited by this paper
• Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study.

  2010cited by this paper
• Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise

  2010cited by this paper
• Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

  2010cited by this paper
• Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.

  2010cited by this paper
• Prevalence of diabetic retinopathy in the United States, 2005-2008.

  2010cited by this paper
• A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes

  2010cited by this paper
• Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230))

  2010cited by this paper
• Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes

  2010cited by this paper
• Assessing the cardio–cerebrovascular safety of vildagliptin: meta‐analysis of adjudicated events from a large Phase III type 2 diabetes population

  2010cited by this paper
• Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: a 6-year follow-up study.

  2010cited by this paper
• Severe hypoglycemia and risks of vascular events and death.

  2010cited by this paper
• The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

  2010cited by this paper
• Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES).

  2009cited by this paper
• Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

  2009cited by this paper
• Early Insulin Treatment in Type 2 Diabetes

  2009cited by this paper
• Defining and Characterizing the Progression of Type 2 Diabetes

  2009cited by this paper
• Barriers to Insulin Injection Therapy

  2009cited by this paper
• The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone

  2009cited by this paper
• Early Insulin Use in Type 2 Diabetes

  2009cited by this paper
• Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

  2009cited by this paper
• Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.

  2009cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009cited by this paper
• Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

  2009cited by this paper
• Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

  2009cited by this paper
• Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

  2009cited by this paper
• Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia

  2009cited by this paper
• Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

  2009cited by this paper
• Three-year efficacy of complex insulin regimens in type 2 diabetes.

  2009cited by this paper
• Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

  2009cited by this paper
• Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database

  2009cited by this paper
• Lifetime Risk of Cardiovascular Disease Among Individuals With and Without Diabetes Stratified by Obesity Status in the Framingham Heart Study

  2008cited by this paper
• Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.

  2008cited by this paper
• 10-year follow-up of intensive glucose control in type 2 diabetes.

  2008cited by this paper
• Hypoglycaemia in Type 2 diabetes

  2008cited by this paper
• Treatment of Type 2 Diabetes With Combined Therapy

  2008cited by this paper
• Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

  2008cited by this paper
• DIABETICMedicine Blackwell Publishing Ltd Original Article: Complications DOI: 10.1111/j.1464-5491.2009.02667.x Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor

  2008cited by this paper
• Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia

  2008cited by this paper
• Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

  2008cited by this paper
• Combined Therapy With Insulin Plus Oral Agents: Is There Any Advantage?

  2008cited by this paper
• Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk: A Population Study of 3.3 Million People

  2008cited by this paper
• Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients

  2008cited by this paper
• Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

  2008cited by this paper
• The Barrier of Hypoglycemia in Diabetes

  2008cited by this paper
• Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

  2008cited by this paper
• A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events

  2007cited by this paper
• Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

  2007cited by this paper
• Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease

  2007cited by this paper
• Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration

  2007cited by this paper
• Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

  2007cited by this paper
• Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.

  2007cited by this paper
• The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes

  2007cited by this paper
• Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy

  2007cited by this paper
• Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

  2007cited by this paper
• Insulin‐associated weight gain in diabetes – causes, effects and coping strategies

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006influential reference
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  2006cited by this paper
• Triple Therapy in Type 2 Diabetes: Insulin Glargine or Rosiglitazone Added to Combination Therapy of Sulfonylurea Plus Metformin in Insulin-Naïve Patients

  2006cited by this paper
• Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936

  2006cited by this paper

• Prescribing patterns before the initiation of novel antidiabetic medicines in public, occupational, and private healthcare: a register study reflecting the guidelines of care in type 2 diabetes

  2024cites this paper
• Bedeutung der Insulintherapie bei Menschen mit Diabetes mellitus Typ 2

  2024cites this paper
• Potentilla anserina L. attenuates oleic acid-induced steatosis in HepG2 cells and hyperlipidemia in high fat diet-induced obese mice

  2023cites this paper
• The Correlation of Prediabetes and Type 2 Diabetes With Adiposity in Adults

  2022cites this paper
• The anti-diabetic drug trelagliptin induces vasodilation via activation of Kv channels and SERCA pumps.

  2021cites this paper
• Characteristics of the clinical treatment of Brazilian and French older adults with diabetes.

  2021cites this paper
• The impact of a co-payment increase on the consumption of type 2 antidiabetics - A nationwide interrupted time series analysis.

  2021cites this paper
• Bariatric Surgery as a Long-Term Treatment for Type 2 Diabetes/Metabolic Syndrome.

  2020cites this paper
• Glycemic Variability, Oxidative Stress and Impact on Complications Related to Type 2 Diabetes Mellitus.

  2020cites this paper
• COMPARISON THE EFFECTIVENESS OF SITAGLIPTIN VERSUS SULFONYLUREA FOR MANAGEMENT OF PATIENTS WITH TYPE II DIABETES MELLITUS

  2019cites this paper
• Pharmacodynamic Evaluation: Diabetic Methodologies

  2019cites this paper
• Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes

  2017cites this paper
• Type 2 diabetes

  2017cites this paper
• Glucose‐lowering drugs

  2017cites this paper
• Optimizing management of glycaemia.

  2016cites this paper
• Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial

  2016cites this paper
• Viscoelasticity as a measurement of clot structure in poorly controlled type 2 diabetes patients: towards a precision and personalized medicine approach

  2016cites this paper
• Incorporating Natural Products, Pharmaceutical Drugs, Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases

  2016cites this paper
• Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review

  2016cites this paper
• Best Practice & Research Clinical Endocrinology & Metabolism

  2016cites this paper
• Current and Emerging Treatment Options in Diabetes Care.

  2016cites this paper
• Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study).

  2016cites this paper
• Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists

  2015cites this paper
• A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus

  2015cites this paper
• COMPARATIVE GLUCOSE-LOWERING AND RENOPROTECTIVE EFFECTS OF SITAGLIPTIN AND INSULIN AND THEIR COMBINED THERAPY ON TYPE-2 DIABETES MELLITUS WITH NEPHROPATHY IN RATS

  2015cites this paper
• The pathogenesis of diabetic neuropathy : a proteomic, metabolomic and electrophysiological investigation

  2015cites this paper
• Clinical utility and patient considerations in the use of the sitagliptin–metformin combination in Chinese patients

  2015cites this paper
• Antidiabetic Drugs: Mechanisms of Action and Potential Outcomes on Cellular Metabolism.

  2015cites this paper
• Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials

  2015cites this paper
• Pyruvate kinase, muscle isoform 2 promotes proliferation and insulin secretion of pancreatic β-cells via activating Wnt/CTNNB1 signaling.

  2015cites this paper
• Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus

  2014cites this paper
• Glucagon signaling in the heart: Activation or inhibition?☆

  2014cites this paper